Table A13:
Study Results—EuroQOL-5D Utilities
| Author, Year N (TAVI/SAVR) | EuroQOL-5D Utilities, Mean Change from Baseline (95% CI) AMD (95% CI), TAVI vs. SAVR | ||
|---|---|---|---|
| 30 Days to 3 Months | 1 Year | 2 Years | |
| Reardon et al, 201719 | 3 months | Not reported | Not reported |
| SURTAVI | TAVI: 0.06 (SD 0.18) | ||
| 1,660 (864/796) | SAVR: 0.05 (SD 0.18) | ||
| 95% Crl of the difference: −0.01 to 0.03 | |||
| Leon et al, 201610 | At 30 days | TAVI: 0.044 (0.029–0.059) | TAVI: 0.027 (0.011–0.043) |
| PARTNER 2, transfemoral cohort | TAVI: 0.058 (0.043–0.072) | SAVR: 0.066 (0.048–0.083) | SAVR: 0.037 (0.018–0.055) |
| SAVR: −0.002 (−0.019 to 0.014) | AMD: −0.011 (−0.031 to 0.008) | AMD: −0.002 (−0.024 to 0.019) | |
| 1,550 (775/775) | AMD: 0.066 (0.047–0.086) | P = .26 | P = .83 |
| P < .001 | |||
| Leon et al, 201610 | At 30 days | TAVI: 0.029 (−0.003 to 0.061) | TAVI: 0.018 (−0.012 to 0.049) |
| PARTNER 2, transthoracic cohort | TAVI: −0.021 (−0.054 to 0.011) | SAVR: 0.032 (0.003–0.060) | SAVR: −0.001 (−0.035 to 0.032) |
| SAVR: −0.022 (−0.055 to 0.010) | AMD: 0 (−0.042 to 0.042) | AMD: 0.018 (−0.029 to 0.065) | |
| 482 (236/246) | AMD: 0.007 (−0.034 to 0.048) | P = .99 | P = .45 |
| P = .72 | |||
Abbreviations: AMD, adjusted mean difference; CI, confidence interval; CrI, credible interval; SAVR, surgical aortic valve replacement; SD, standard deviation; TAVI, transcatheter aortic valve implantation.
aConsidered a substantial or moderate improvement.